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The Kidney Disease Outcomes Quality Initiative definition
and staging of chronic kidney disease (CKD) have been
adopted by most nephrologists but include a criterion of
chronicity that has not been investigated. This criterion
specifies that renal structural damage and/or reduction in
glomerular filtration rate (GFR) should be present for periods
lasting longer than 3 months. We examined the effects of
changing this criterion to 6, 9, or 12 months on the prognosis
and the rate of progression in population-based cohorts with
CKD stages 3 and 4. A 12-month chronicity criterion
significantly reduced the number of CKD patients relative to
the 3-month criterion for both stages 3 and 4. For both
stages, there were statistically significant differences in 5-year
mortality between the 6- and 9-month cohorts. For stage 4,
the 5-year cumulative incidence of renal failure significantly
increased from 6 to 9 months, and the rate of change in GFR
significantly decreased between the same two cohorts. The
5-year cumulative incidence of improvement in GFR lasting
1 year or more was significantly higher for the 3-month
cohort than for the 12-month cohort in the stage
3 group. Hence, we suggest that the chronicity criterion
is an important determinant of the characteristics of
the population of patients with CKD stages 3 and 4.
This may have practical consequences in both research
and clinical work.
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The increasing demand for renal replacement therapy has
made the search for effective therapy for the predialytic stages
of chronic kidney disease (CKD) more important.
A commonly accepted definition for classifying these stages
is necessary both for research and for developing clinical
guidelines. The National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (K/DOQI) definition and
classification scheme for CKD, published in 2002, goes a
long way toward fulfilling this need.1
The goal of the K/DOQI Work Group was to set criteria
that allowed unequivocal decisions about the diagnosis and
staging of CKD.2 The staging scheme was based on the
presence of kidney damage and/or reduced glomerular
filtration rate (GFR). The more advanced stages of CKD
are defined by reduced GFR alone with GFR cutoff values
between stages of 60, 30, and 15 ml/min/1.73 m2. For
exclusion of acute forms of kidney disease, the reduced
GFR should persist for 3 months or more; however, the Work
Group stated that both the cutoff levels and the 3-month
criterion were chosen arbitrarily.2
This information raises the question of how optimal these
criteria are. In particular, there is a concern that the 3-month
requirement is too short to exclude conditions with
subsequent improvement in GFR from stages 3 and 4.
In addition, a patient could theoretically run the gamut of
stage 3 from 59 to 30 ml/min/1.73 m2 in 3 months and still
meet the given criteria for CKD, even though the overall rate
of decrease would be 120 ml/min/1.73 m2/year. Such a
scenario would not conform to the common clinical notion
of a chronic condition, but whether this is a problem in
practical staging needs to be clarified.
Therefore, we explored how variations in this criterion
affect mortality, risk of kidney failure, and rate of decrease in
GFR for CKD stages 3 and 4. Data were obtained from a
complete database of all serum creatinine measurements
performed in a well-defined population for 10 years.
RESULTS
Of the 38 241 patients with one or more measurements of
creatinine, 1225 were categorized into CKD stage 3 (3.2%)
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and 138 into CKD stage 4 (0.4%), based on the 3-month
criterion. The median number of creatinine measurements
for the CKD stage 3 patients, including those made in the
defining time interval, was 11 (interquartile range, 6–22), and
for the stage 4 patients, it was 13 (interquartile range, 6–23).
Table 1 shows the number of patients in the groups based
on varying the duration requirement. Changing the criterion
to 12 months decreased the number of identified patients by
37 and 51% for CKD stages 3 and 4, respectively, relative to
the 3-month requirement.
Outcomes
Table 1 shows the cumulative incidences of each of the three
competing end points. Although the 5-year mortality was
similar for the 3-month cohorts from both stages 3 and 4
(45.9 vs 43.7%), there was a statistically significant decrease
between the 6- and 9-month cohorts for both stages.
Mortality for the 12-month cohort was higher for stage 3
than for stage 4 (40.3 vs 27.1%). To explore this difference, an
ordinary Kaplan–Meier survival analysis with death as the
only end point and censoring at the end of study was
performed for both 12-month cohorts. The 5-year mortality
was then 43.9 and 58.8% for CKD stages 3 and 4, respectively,
indicating that patients having reached the renal failure end
point in stage 4 had a high mortality.
Although the cumulative incidence of renal failure
remained at the 4% level for all cohorts of stage 3, there
was a sharp increase from 47.5 to 59.5% between the 6- and
9-month cohorts for stage 4.
No patient with CKD stage 4 experienced the improve-
ment end point. For stage 3, the cumulative incidence
of this end point decreased gradually from 4.8% for the 3-
month cohort to 2.3% for the 12-month cohort. The
differences between both the 3- and 6-month cohorts and
between the 6- and 9-month cohorts at stage 3 were
statistically significant.
Table 2 shows the results of the Cox regression for each
end point. For CKD stage 3, the hazard ratios were
significantly lower for all three end points in patients who
satisfied the 12-month criterion. Also, there were statistically
significant linear trends for a decrease in hazard ratio for each
end point from the 3- to the 12-month criterion (Po0.001).
Analysis of the composite end point of death or renal failure,
and of death alone, showed similar results as for death in
Table 2 (data not shown).
In stage 4, there was also a significant linear trend for a
decreasing hazard ratio for death with a longer duration
criterion (Po0.001) (Table 2). For renal failure, there was a
strong tendency toward a higher hazard ratio for those
satisfying the longest criteria (P¼ 0.07). There were no
significant differences between the patient groups for the
composite end point, probably because its two-component
end points showed opposite tendencies.
Increased age was associated with an increased hazard
ratio for death for both CKD stages 3 and 4, whereas a
decreased hazard ratio for renal failure for stage 3 was found.
Female gender and increased baseline GFR had a positive
effect only for death and renal failure in stage 3.
Table 1 | Comparision between different criteria of chronicity for CKD stages 3 and 4










N 1225 1025 881 774
Percent women 57 55–60 57 53–60 57 53–60 56 53–60
Mean age 76.4 75.8–77.1 76.5 75.8–77.2 76.7 75.9–77.5 77.0 76.2–77.8
Mean baseline GFR,
ml/min/1.73 m2
50.9 50.4–51.3 50.8 50.3–51.2 50.6 50.1–51.1 50.7 50.1–51.2
5-year cumulative incidence, percent
Renal failure 4.2 2.9–5.7 4.1 2.7–5.7 4.6 3.0–6.5 4.5 2.8–6.5
Patient death 45.9 42.6–49.2 44.6* 41.0–48.2 42.1* 38.3–46.1 40.3 36.3–44.6
Improvement in GFR 4.8* 3.5–6.2 3.7* 2.5–5.1 2.8 1.8–4.1 2.3 1.3–3.6
CKD stage 4
N 138 111 90 68
Percent women 43* 36–52 48 39–57 44 34–55 46 34–58
Mean age 74.5 71.8–77.1 74.8* 71.7–77.5 73.3 69.8–76.5 72.5 68.2–76.2
Mean baseline GFR,
ml/min/1.73 m2
24.8 24.0–25.5 24.8 24.0–25.5 24.6 23.7–25.5 25.1 24.0–26.0
5-year cumulative incidence, percent
Renal failure 43.1* 33.6–53.0 47.5* 36.9–59.0 59.5 47.8–72.5 64.0 51.1–78.5
Patient death 43.7 34.3–53.3 43.0* 32.6–54.3 31.5 21.0–43.5 27.1 16.1–39.8
Improvement in GFR 0.0 0.0 0.0 0.0
CKD, chronic kidney disease; GFR, glomerular filtration rate.
*Po0.05 for difference from the next cohort
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Some patients were censored before they had creatinine
measurements to allow determination of whether they
belonged to the 6-, 9-, or 12-month cohorts. There were 92
of these patients in stage 3 and 10 in stage 4. All analyses were
repeated after they were excluded, and the results did not
differ materially from those presented in the tables.
Rate of progression
Table 3 shows the estimated mean change in GFR (DGFR) for
each stage and each of the four nested cohorts. For CKD stage
3, there was a change from 1.5 ml/min/1.73m2/year for the
3-month cohort to 2.1 ml/min/1.73m2/year for the 12-
month cohort. The minus sign indicates a decrease in GFR.
The percentage of patients with a decrease in GFR increased
from 71 to 80. In the two-level multivariate linear regression
analysis with dummy variables for the longest duration
criterion satisfied as covariates, there was a significant linear
trend of lower DGFR with a longer duration criterion. Female
gender was associated with a slower decrease (Table 4).
For CKD stage 4, mean DGFR varied from 2.7 to
4.2 ml/min/1.73 m2/year from the 3-month to the 12-
month cohort, and the percentage of patients with decreasing
GFR increased from 84 to 91 (Table 3). In the regression
analysis, the 6-month criterion had a significantly higher
regression coefficient than the reference, and the linear trend
of lower DGFR with a longer duration was significant
(Table 4).
Nonlinear relationships between DGFR and time were
explored with inclusion of quadratic and cubic terms in the
models for both stages, but were not statistically significant.
DISCUSSION
The importance of agreeing on definitions of nosological
entities can hardly be overstated. Progress in clinical work
and research depends on a solid conceptual foundation, and
new definitions should be tested under field conditions
before they are accepted. In this study, we applied the
K/DOQI definitions of CKD stages 3 and 4 to a clinical
database of creatinine measurements to examine the criterion
of chronicity. Because the database included all detected
kidney disease in a well-defined population, the results show
the spectrum of disease that can be expected from ordinary
use of the definitions.
Results for the 3-month cohort of CKD stage 3,
corresponding to the established definition, showed a high
mortality and a low risk of renal failure at 5 years and a low
rate of decrease in GFR. This patient population has been
discussed in more detail in a separate publication.3 It is
noteworthy that for this group, the risk of re-establishing
GFR at a level greater than 60 ml/min/1.73 m2 was about the
Table 2 | Cox regression analyses of the competing end points death, renal failure, and improvement in GFR for CKD stages 3
and 4













CKD stage 3 (n=1225)
Female gender 0.56 0.47–0.67 o0.001 0.46 0.27–0.81 0.007 1.52 0.78–2.95 0.22
Age, 10-year increment 1.90 1.71–2.12 o0.001 0.78 0.64–0.96 0.02 0.83 0.65–1.05 0.12
Baseline GFR, 10 ml/min/
1.73 m2 increment
0.82 0.74–0.91 o0.001 0.61 0.45–0.82 0.001 1.40 0.90–2.17 0.13
Longest duration criterion satisfied
3 month 1.00 Reference 1.00 Reference 1.00 Reference
6 month 1.20 0.89–1.62 0.22 0.79 0.26–2.43 0.68 0.69 0.26–1.81 0.45
9 month 0.84 0.60–1.17 0.30 0.57 0.19–1.71 0.31 0.64 0.24–1.68 0.36
12 month 0.26 0.20–0.33 o0.001 0.16 0.07–0.37 o0.001 0.15 0.07–0.31 o0.001
Linear trend o0.001 o0.001 o0.001
CKD stage 4 (n=138)
Female gender 1.11 0.60–2.05 0.74 0.85 0.46–1.58 0.62
Age, 10-year increment 2.01 1.49–2.71 o0.001 0.91 0.79–1.06 0.21
Baseline GFR, 10 ml/min/
1.73 m2 increment
0.64 0.31–1.32 0.13 0.68 0.35–1.34 0.27
Longest duration criterion satisfied
3 month 1.00 Reference
6 month 1.70 0.74–3.89 0.21 1.00b Reference
9 month 0.57 0.22–1.47 0.25
12 month 0.37 0.17–0.80 0.01 2.22c 0.94–5.27 0.07
Linear trend o0.001
CKD, chronic kidney disease; GFR, glomerular filtration rate.
aNo patient with the CKD stage 4 experienced the improvement end point.
bThe 3- and 6-month category combined because of few end points.
cThe 9- and 12-month category combined.
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same as that of developing renal failure. On the other hand,
the 3-month cohort from the stage 4 group had both a high
risk of renal failure and death and a steeper decrease in GFR.
The most important consequence of increasing the time
period was a reduction in the number of patients by 16–37%
for stage 3 and by 20–51% for stage 4 (Table 1). Analyses of
the competing end points showed statistically significant
differences between the cohorts. In both stages, the shorter
duration criteria included patients with a higher mortality
(Table 2) and a slower decrease in GFR (Tables 3 and 4). For
stage 3, they also had a significantly higher chance of
improvement in GFR to a level greater than 60 ml/min/
1.73 m2. For stage 4, there was a marked increase in the
cumulative incidence of renal failure and a decrease in the
cumulative mortality between the 6- and 9-month cohorts
(Table 1). The regression analyses demonstrated that the
effects of varying the duration criterion were independent of
age, gender, and baseline GFR.
The 12-month cohort from the stage 4 group exhibited a
lower mortality than the 12-month cohort from the stage 3
group, which may seem paradoxical. This outcome arose
from the increased hazard of renal failure for stage 4 patients,
which preempted the mortality end point. Many patients in
stage 4 who reached the renal failure end point first
Table 3 | Change in GFR for different criteria of chronicity in CKD stages 3 and 4










N 1225 1025 881 774
DGFR, ml/min/1.73 m2/yeara
Mean 1.5 1.7 to 1.3 1.6 1.8 to 1.4 1.8 2.0 to 1.6 2.1 2.4 to 1.9
Standard deviation 4.2 3.6 3.5 3.4
Patients with DGFRo0, percent 71 69–74 75 72–77 77 74–80 80 78–83
CKD stage 4
N 138 111 90 68
DGFR, ml/min/1.73 m2/yeara
Mean 2.7 3.4 to 2.1 3.3 3.9 to 2.6 4.1 4.8 to 3.5 4.2 4.9 to 3.4
Standard deviation 3.7 3.6 2.9 3.1
Patients with DGFRo0, percent 84 78–90 86 79–92 90 84–96 91 84–98
CKD, chronic kidney disease; GFR, glomerular filtration rate.
aDGFR, change in GFR, negative values denote a decrease in GFR.
Table 4 | Effects on change in GFR (DGFR) of age, gender, and chronicity criterion for CKD stages 3 and 4 in two-level





CKD stage 3 (n=1225)
DGFR for 60-year-old male satisfying only the 3-month criteriona 1.1 3.1 to 0.8 0.26
Female gender 1.3 0.2 to 2.4 0.02
Age, 10-year increment 0.1 0.5 to 0.4 0.73
Longest duration criterion satisfied
6 month 0.2 3.1 to 2.6 0.87
9 month 0.6 2.0 to 3.3 0.64
12 month 1.6 3.4 to 0.2 0.09
Linear trend 0.03
CKD stage 4 (n=138)
DGFR for 60-year-old male satisfying only the 3-month criterion 1.9 5.0 to 1.2 0.24
Female gender 0.1 2.3 to 2.1 0.92
Age, 10-year increment 0.1 0.6 to 0.7 0.81
Longest duration criterion satisfied
6 month 6.2 1.1 to 11.2 0.02
9 month 2.2 6.4 to 1.9 0.29
12 month 2.4 5.7 to 0.9 0.16
Linear trend 0.01
CKD, chronic kidney disease; GFR, glomerular filtration rate.
aDGFR, change in GFR, negative values denote a decrease in GFR.
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subsequently died, as demonstrated in an ordinary Kaplan–-
Meier survival analysis in which death was analyzed as the
only end point.
Because creatinine is assumed to vary little in non-
hospitalized patients, some epidemiological surveys have not
included the chronicity criterion in estimates of CKD
prevalence.4,5 In the third National Health and Nutrition
Examination Survey, the prevalence of different CKD stages
was estimated from one measurement of creatinine in each
patient.6 However, a repeat measurement of a random sample
of the subjects found that only 77% of those classified as
o60 ml/min/1.73 m2 were classified similarly on the repeat
measurement. Classification based on a single measurement
would therefore tend to inflate the prevalence estimates. This
indicates that a chronicity criterion should also be used in
population surveys. For epidemiologic studies based on
creatinine measured in patients, this criterion is indispen-
sable and was used in recent studies by both Keith et al.7 and
Drey et al.8 Unfortunately, it is not possible to determine
from these papers how use of this criterion affected the
number of patients identified for the studies.
The CKD definitions are also used as inclusion criteria in
clinical trials. Estimating the necessary sample size depends
on the expected frequency of the primary end point. In
studies of interventions to slow the progression of CKD, a
high percentage of patients with stable GFR would necessitate
an increase in the number of patients required. A longer
duration criterion would lessen this problem because the 12-
month cohorts of both stages exhibited the lowest mean and
standard deviations of DGFR. An alternative solution would
be to specify additional inclusion criteria, such as protein-
uria, to limit the number of patients without progressive
disease; however, this tactic would prevent generalization of
the results to all patients with CKD, which again would make
the definition less useful. In addition, including CKD stage 4
patients from the 3- and 6-month cohorts would result in
selection of study populations with very high mortality, a
potential problem in some types of studies.
The K/DOQI CKD definition has played an important role
in the development of practice guidelines.9 The results of this
study show that definitions based on short duration criteria
result in identification of large cohorts including many patients
with poor prognosis. Although these patients must also receive
treatment and care, they probably have other needs than, for
example, a patient with a decreasing GFR and a longer life
expectancy. Practice guidelines target groups of patients, but
should nevertheless be as specific as possible. This need for
specificity is an argument for making the target populations as
homogeneous as possible and accordingly for the use of a
definition with a longer duration criterion.
The mean age in our cohort of CKD patients was high.
This is a consequence of the natural decrease in GFR with age
and the application of the same GFR cutoffs to all age groups
in the definition. Other studies have made similar findings
and advocated different cutoffs for the elderly.10 Population
surveys have also found a very high prevalence of CKD stages
3 and 4 in the older age groups, even though elderly and
diseased people are probably underrepresented in sur-
veys.11–13 As our cohort included all patients with detected
CKD in a well-defined population, it is more representative
of the CKD patients who are met by the nephrologists in
clinical practice. However, similar studies need to be done in
populations with different ethnic compositions and health-
care systems before the optimal chronicity criterion can be
defined.
The limitations of estimating GFR from serum creatinine
are well known.14 One of the most significant limitations is
the lack of calibration of creatinine analysis across labora-
tories; this limitation is illustrated by the differences in some
of the results presented here for CKD stage 3 compared with
those in a previous publication based on the same database.3
The recalibration of the Modification of Diet in Renal Disease
equation for isotope dilution mass spectrometry traceable
creatinine measurement methods and the recalculation of
creatinine values measured with Jaffe’s method for the
enzymatic method in our laboratory represent a substantial
improvement in the accuracy of the estimates. This
improvement was confirmed by comparison of a sample of
the estimates to 51CrEDTA clearance.
We conclude that the choice of chronicity criterion in the
CKD definitions for stages 3 and 4 was a determinant of the
characteristics of the identified patient populations, particu-
larly of the number of patients identified. This finding may
have important implications for how the definitions are




The database of the Department of Medical Biochemistry at the
University Hospital of North Norway contains all measurements of
serum creatinine performed on inhabitants of the municipality of
Tromsø in northern Norway. In the 10-year study period from
January 1, 1994 to December 31, 2003, there were 248 560
measurements of creatinine in these subjects as part of routine
clinical activities. These activities included all healthcare in the
municipality, both primary care and hospital in- and outpatients,
and amounted to 0.43 measurements per person-year in the total
population.3 The mean population of Tromsø in the study period
was 58 086. The University Hospital of North Norway is the sole
provider of nephrology and laboratory services, ensuring the
completeness of the database; the distance to the next laboratory
and hospital is 300 km by road. The study population and the
database have been described in more detail previously.3
Measurements
Serum creatinine analyses were performed with instruments from
Roche Diagnostics (Mannheim, Germany). The model Hitachi 917
was used from 1994 to 2002, with a switch in 2002 to the Modular
model from Hitachi. A Jaffe method with reagents and calibrators
purchased from the same company also was used. Control samples
with three levels of creatinine were analyzed for every 100 patient
samples. For internal quality control, we used an analytical
coefficient of variation of 2%. The rejection rule was the occurrence
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of two consecutive control observations exceeding the same
mean72 s.d. Calibrations were performed when necessary. The
laboratory participated in an External Quality Assessment Program
provided by Labquality (Helsinki, Finland).
At the end of 2003, a new enzymatic method for creatinine
analysis was introduced in our laboratory (CREA Plus, Roche
Diagnostics), which has been standardized against isotope dilution
mass spectrometry. The linear relationship between the old and the
new methods was established and permitted recalculation of all of
the old creatinine values to the enzymatic method.
Levey et al.15 recently published a new version of the abbreviated
Modification of Diet in Renal Disease formula recalibrated for isotope
dilution mass spectrometry traceable creatinine measurement meth-
ods. The formula estimates GFR from creatinine, gender, and age as
175 (serum creatinine)1.154 age0.203 0.742 for women and
 1.21 if African-American.15 GFR was estimated using this formula
for all the recalculated creatinine measurements in the database. Only
measurements before initiation of first-time renal replacement therapy
(RRT) were included. The database included date of birth and a
person number encoding gender. Age at the time of measurement was
used for each estimate. The number of inhabitants of African descent
in Tromsø is negligible, and this last factor was ignored.
To validate the GFR estimates, these values were compared with
all available concurrent measurements of 51CrEDTA clearance.
Because the abbreviated Modification of Diet in Renal Disease
formula is known to be imprecise for higher GFR values, only
51CrEDTA clearances below 100 ml/min/1.73 m2 were included.
A total of 80 measurements were found. When the difference
between estimated GFR and 51CrEDTA clearance was expressed as
percentage of 51CrEDTA clearance, the median of the distribution of
differences was 16.3%, the 75th percentile was 27.3%, and the 90th
percentile was 40%. Although these values are somewhat higher
than those published by Levey for the original, abbreviated
Modification of Diet in Renal Disease formula (the same percentiles
were 12.1, 20.5, and 29.7%), this precision was deemed sufficient for
the purposes of this study (Levey AS, Greene T, Kusek JW et al. J Am
Soc Nephrol 2000; 11: A0828, abstract).
In a previous publication regarding CKD stage 3 from this
project, estimated GFR values from Jaffe creatinine measurements
were used, and some of the results for the CKD stage 3, 3-month
cohort presented here differ somewhat from our previous
estimates.3 The most important difference is a decrease in the
number of patients classified as CKD stage 3.
Classification of CKD
According to the K/DOQI definition, GFR from 30 to 59 ml/min/
1.73 m2 is classified as CKD stage 3, and from 15 to 29 ml/min/
1.73 m2 as CKD stage 4.2 For each stage, all GFR estimates in the
corresponding interval were identified. When an identified mea-
surement was followed by a second measurement in the same
interval 3 months or more after the first, the patient was classified as
being in the corresponding stage if there were no measurements
outside the interval in the time period between these two.
This process was then repeated three times, but with the
requirement of a second measurement at 6, 9, and 12 months after
the first, instead of at 3 months. Because all patients who satisfied,
for example, the 9-month criterion also satisfied the 3- and
6-month criteria, we had four nested cohorts of patients (Figure 1).
The observation time of each patient was defined as starting 3, 6,
9, or 12 months after the date of the first registered measurement
that satisfied these criteria.
Outcomes
Death, renal failure, and improvement were considered competing
risks. Renal failure was defined as either initiation of RRT or CKD
stage 5, and the date of the event that occurred first was registered.
CKD stage 5 is defined as GFR o15 ml/min/1.73 m2 and was
ascertained from the database as the first date of a GFR below this
level with no subsequent values of 15 or greater before RRT, death,
or censoring.1
Improvement was registered as the first date with estimated GFR
equal to or greater than 60 ml/min/1.73 m2 followed by a second
measurement above this level at least 1 year later with no values
below this level in the interim. Patients were censored at the end of
the study period.
All initiation of RRT for inhabitants of the municipality is
administered by the University Hospital of North Norway, and the
date was recorded from hospital databases. Initiation of RRT in
patients who had moved from the municipality was assumed to be
negligible, as migration in people over 40 years of age to and from
the municipality was very low during the period.16
As an additional validation of the completeness of the creatinine
database, it was matched with all patients from Tromsø having
initiated RRT in the study period. Only four of 55 patients did not
have any creatinine measurement in the 3 months before the start of
RRT. In two of these, RRT was started within 3 months of the
beginning of the study period.
Date of death was registered from the hospital’s database, which
is regularly updated against the Norwegian Central Population
Register.
Statistical analysis
Identical and separate statistical analyses were done for the CKD
stage 3 and 4 groups.
DGFR expressed in ml/min/1.73 m2/year was estimated for each
patient with a two-level multivariate linear regression model. DGFR
was modeled as a linear function of time incorporating age and













Figure 1 | Nested cohorts with different duration criteria in CKD
stage 3.
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and a positive change an improvement. Compared to using ordinary
least-square estimates of change in GFR for each individual patient,
this method avoids high variability in estimates for patients with
short follow-up. The model has been described in more detail
previously.3 First, separate analyses were done for each of the four
cohorts which included all measurements made after the respective
defining time intervals until death, initiation of RRT, or end of
follow-up. These estimates were used for calculating the mean DGFR
with confidence intervals for each cohort. Secondly, an analysis was
done including all patients where dummy variables for the longest
duration criterion satisfied by each patient were added as covariates.
Linear trends were investigated with the chronicity criterion entered
as a continuous variable. PROC MIXED in SAS was used for
estimating the parameters of the model (SAS Institute, Cary, NC).
Survival analysis of the competing risks of death, renal failure,
and improvement was performed using non-parametric, maximum
likelihood estimates of the cumulative incidence of each end point
in the presence of the other end points, as suggested by Kalbfleisch
and Prentice.17 This analysis was done separately for each of the
cohorts. Because of statistical dependences between these four
nested cohorts, ordinary statistical tests of differences could not be
used. Instead, 95% confidence intervals for the outcomes of each
cohort and differences between them were estimated with the
bootstrap algorithm using 20 000 resamples of the original
observations.18
The differences in hazard rates were analyzed in Cox regression
of time until each of the three end points. Independent variables
were age, gender, baseline GFR, and dummy variables for the longest
duration criterion satisfied by each patient. For each analysis,
patients were censored when experiencing any of the competing end
points or at the end of follow-up.17
Because patients might experience death or renal failure after the
improvement end point, additional Cox regressions were performed
of the composite end point of renal failure or death, and of death
alone, with patients censored only at end of follow-up. The
independent variables were the same.
Statistical significance was set at Po0.05. This study was
approved by the Norwegian Data Inspectorate and the Regional
Ethics Committee of North Norway.
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